Standard BioTools prelim Q4 revenue ~$56M, FY2025 ~$185M; SomaLogic sale on track

STANDARD BIOTOOLS INC.

2025-FY EPS reported -$0.20 revenue$85,331,000

Q4 combined rev ~$56M (continuing ops ~$24M); FY2025 combined ~$185M (continuing ~$85M).
Exceeded guidance and expectations for both combined and continuing operations.
SomaLogic sale to Illumina on track to close H1 2026; expects ~$550M cash post-close.
Base business on track to positive adjusted EBITDA; positioned for disciplined M&A.
Streamlined operations and improved cost structure exiting year as leaner organization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.